CEO : Hans Bishop

CEO : Marina Udier-Blagovic

Led by successful entrepreneurs with prior experience in developing innovative candidate vaccines for infectious diseases , Nouscom ’ s platform technology is based on recombinant Adenovirus isolated from non-human great apes ( GAd ) and Modified Vaccinia Virus Ankara ( MVA ).

Evaluated in more than 4,000 adults , newborns , and elderly healthy subjects , as well as those with chronic infectious diseases , Nouscom states that the vaccine therapy has shown to be safe and effective , and will continue to leverage its expertise and experience to further develop its therapies .

Combining science , technology and population-scale clinical studies , GRAIL ’ s mission is to detect cancer early in patients . Through continuous collaboration , high intensity sequencing , and modern data science , GRAIL is working to create vast datasets to develop evidence that supports its products .

Such projects include the development of a blood test which combines high-intensity genomic sequencing and complex computational algorithms to find cancer-specific patterns to detect multiple types of cancer .